Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation.
Smeitink J, van Es J, Bosman B, Janssen MCH, Klopstock T, Gorman G, Vissing J, Ruiterkamp G, Edgar CJ, Abbink EJ, van Maanen R, Pogoryelova O, Stendel C, Bischoff A, Karin I, Munshi M, Kümmel A, Burgert L, Verhaak C, Renkema H.
Smeitink J, et al. Among authors: janssen mch.
Brain. 2024 Nov 6:awae277. doi: 10.1093/brain/awae277. Online ahead of print.
Brain. 2024.
PMID: 39501914